Published in Ther Drug Monit on April 01, 1995
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos (1992) 1.59
Pharmacokinetics of FK 506 in transplant patients. Transplant Proc (1991) 1.30
In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys (1992) 1.21
A whole blood FK 506 assay for the IMx analyzer. Transplant Proc (1991) 1.21
Practical aspects of FK 506 analysis (Pittsburgh experience). Transplant Proc (1991) 1.19
Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. Transplant Proc (1990) 1.08
Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. Clin Chem (1992) 0.97
FK 506 assay past and present--characteristics of FK 506 ELISA. Transplant Proc (1991) 0.93
Monitoring FK 506 concentrations in plasma and whole blood. Transplant Proc (1991) 0.92
A combined HPLC-ELISA evaluation of FK 506 in transplant patients. Transplant Proc (1991) 0.87
High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. Transplant Proc (1991) 0.84
Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood. Clin Chem (1992) 0.82
Multicenter comparison of tacrolimus (FK 506) whole blood concentrations as measured by the Abbott IMX analyzer and enzyme immunoassay with methylene chloride extraction. Ther Drug Monit (1994) 0.82
Metabolism of FK 506 in differentially induced rat liver microsomes. Res Commun Chem Pathol Pharmacol (1992) 0.79
FK506 measurement: comparison of different analytical methods. Ther Drug Monit (1993) 0.79
Comparison of different assays for the quantitation of FK 506 levels in blood or plasma. Ther Drug Monit (1994) 0.79
Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. J Chromatogr (1990) 0.78
Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. Clin Chem (1993) 0.77
Validation and quality assurance program for monitoring tacrolimus (FK 506) concentrations in plasma and whole blood. Ther Drug Monit (1993) 0.77
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Kidney transplantation under FK 506. JAMA (1990) 7.45
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Illuminating the 'black box'. A description of 4454 patient visits to 138 family physicians. J Fam Pract (1998) 4.70
IMMUNOSUPPRESSION WITH FR 900506 FOR CANINE KIDNEY AND LIVER TRANSPLANTATION. Surg Res Commun (1987) 4.68
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci U S A (1984) 3.91
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Water metabolism in relation to the menstrual cycle. J Physiol (1937) 3.72
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet (1986) 3.53
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42
Components of histidine transport: histidine-binding proteins and hisP protein. Proc Natl Acad Sci U S A (1970) 3.39
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Factors in sexual-skin oedema. J Physiol (1938) 3.27
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Some Effects of Oestrin on the Menstrual Cycle of Baboons and Macaques. J Anat (1931) 3.13
The occurrence of an oestrogenic substance in the sexual skin of monkeys. Biochem J (1936) 3.06
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst (2001) 2.83
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet (1997) 2.81
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther (1985) 2.38
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol (1988) 2.21
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
How did Medicare's prospective payment system affect hospitals? N Engl J Med (1987) 2.05
Cilia with defective radial spokes: a cause of human respiratory disease. N Engl J Med (1979) 2.01
Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96
Role of murein lipoprotein in morphogenesis of the bacterial division septum: phenotypic similarity of lkyD and lpo mutants. J Bacteriol (1978) 1.94
Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg (2000) 1.89
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension (1995) 1.86
Profits and fiscal pressure in the prospective payment system: their impacts on hospitals. Inquiry (1989) 1.85
Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85
Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83
Outcome of preimplantation genetic diagnosis of translocations. Fertil Steril (2000) 1.78
Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc (1993) 1.78
The Endocrine Control of the Prostate: (Section of Urology). Proc R Soc Med (1936) 1.77
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75
Small intestinal transplantation in humans with or without the colon. Transplantation (1994) 1.74
Medicaid managed care in thirteen states. Health Aff (Millwood) (1998) 1.71
Directly labeled DNA probes using fluorescent nucleotides with different length linkers. Nucleic Acids Res (1994) 1.71
Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm (1995) 1.69
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69
Receipt of preventive health care services by lesbians. Am J Prev Med (2000) 1.67
EMG responses to maintain stance during multidirectional surface translations. J Neurophysiol (1998) 1.67
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem (2001) 1.67
Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis (1985) 1.61
The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc (1991) 1.60
PCR primers for human chromosomes: reagents for the rapid analysis of somatic cell hybrids. Genomics (1991) 1.58
Lesbians' sexual history with men: implications for taking a sexual history. Arch Intern Med (2000) 1.57
New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc (1991) 1.56
Cost of practice and geographic variation in Medicare fees. Health Aff (Millwood) (1989) 1.56
Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients. Transplant Proc (1985) 1.55
Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant (2006) 1.55
Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant (2013) 1.54
Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem (1994) 1.49
Family physicians' disagreements with the US Preventive Services Task Force recommendations. J Fam Pract (1994) 1.47
Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation (2001) 1.47
Functional outcome of thoracolumbar burst fractures without neurological deficit. J Orthop Trauma (1996) 1.47
Transposition of ciliary microtubules: another cause of impaired ciliary motility. N Engl J Med (1980) 1.45
Pharmacokinetics of orally administered ritodrine. Am J Obstet Gynecol (1989) 1.45
Degradation of apolipoprotein B-100 of human plasma low density lipoproteins by tissue and plasma kallikreins. J Biol Chem (1984) 1.44
Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg (2001) 1.44
Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology (2000) 1.44
Prostasin is a glycosylphosphatidylinositol-anchored active serine protease. J Biol Chem (2001) 1.43
Confirming insurance coverage in a telephone survey: evidence from the National Survey of America's families. Inquiry (2000) 1.42
Intestinal transplantation at the University of Pittsburgh. Transplant Proc (1994) 1.42
A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40
Control of stance during lateral and anterior/posterior surface translations. IEEE Trans Rehabil Eng (1998) 1.39
The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements. J Clin Endocrinol Metab (1980) 1.39
Combined liver-kidney transplantation: analysis of patients with preformed lymphocytotoxic antibodies. Transplant Proc (1988) 1.38
FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37
Abdominal multivisceral transplantation. Transplantation (1995) 1.37
Autopsy findings in a long-surviving liver recipient. N Engl J Med (1973) 1.36
Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA. J Biol Chem (1995) 1.35
Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem (1992) 1.34
Assay of FK 506 in plasma. Transplant Proc (1990) 1.32
Variation in the sensitivity of different species of monkeys to oestrin. J Physiol (1935) 1.32
Inducible, brain region-specific expression of a dominant negative mutant of c-Jun in transgenic mice decreases sensitivity to cocaine. Brain Res (2003) 1.31